Drug reimbursement in the UK: What impact of value-based pricing?

25 May 2011

The UK's coalition government has embarked on a set of health care reforms designed to transform the country's National Health Service and, among those, the introduction of Value-Based Pricing (VBP) is set to radically change the way medicines are priced and reimbursed in the country.

The key concern for pharmaceutical companies is that the reform could end free pricing of pharmaceuticals in the country; in light of this, IHS Global Insight examines the current UK pricing and reimbursement system and the likely changes to this system following the introduction of VBP.

Key findings

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK